{"database": "openregs", "table": "documents", "rows": [["FDA-2005-D-0208-0002", "FDA", "FDA-2005-D-0208", "Guidance for Industry: Safety, Efficacy, and Pharmacokinetic Studies to Support Marketing of Immune Globulin Intravenous (Human) as Replacement Therapy for Primary Humoral Immunodeficiency; Draft Guidance Document", "Other", "GDL-Guidance (Supporting and Related Materials)", "2005-12-02T05:00:00Z", 2005, 12, null, null, "2008-07-18T05:20:46Z", null, 0, 0, "090000648044123a"]], "columns": ["id", "agency_id", "docket_id", "title", "document_type", "subtype", "posted_date", "posted_year", "posted_month", "comment_start_date", "comment_end_date", "last_modified", "fr_doc_num", "open_for_comment", "withdrawn", "object_id"], "primary_keys": ["id"], "primary_key_values": ["FDA-2005-D-0208-0002"], "units": {}, "query_ms": 100.75551609043032, "source": "Federal Register API & Regulations.gov API", "source_url": "https://www.federalregister.gov/developers/api/v1", "license": "Public Domain (U.S. Government data)", "license_url": "https://www.regulations.gov/faq"}